Savara Inc.

SVRA

$4.95

Updated: 23/09/2026, 20:06:13

Market Cap

$1.02B

Sector

Healthcare

Industry

Biotechnology

Country

Stock valuation chart

One-year closing share-price history for SVRA

Company Profile

Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.

USD

NASDAQ

CEO: Matthew Pauls

Employees: 70

https://www.savarapharma.com

Asset Summaries

Latest generated summaries for SVRA

No summaries found.

Detailed business

Structured knowledge from the latest official annual filing.

No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.

Full company information

Latest profile, trading, valuation, and identifier data stored for SVRA.

Share price: $4.95
Market cap: $1.02B
Exchange: NASDAQ
Currency: USD
CEO: Matthew Pauls
Employees: 70
IPO date: 28/04/2017
Beta: 0.252
Last dividend: $0.00
Day range: $4.92 – $5.35
52-week range: $3.34 – $7.01
1-day performance: -6.53%
1-year performance: 48.32%
Current drawdown (1Y): -29.28%
CIK: 0001160308
CUSIP: 805111101
ISIN: US8051111016
Created: 07/12/2025, 14:26:48
Last update: 23/09/2026, 20:06:13

Track Savara Inc. with an AI analyst

See which prediction-market events move SVRA, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Create a free account See what the world decides next

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News

News linked to SVRA from your Railway `news_articles` table.

Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Business Wire • STOCK • 19/05/2026, 16:15:00

Savara Announces New Employment Inducement Grant

Business Wire • STOCK • 17/04/2026, 18:05:00

Savara To Present New Data at the American Thoracic Society (ATS) 2026 International Conference

Business Wire • STOCK • 14/04/2026, 10:05:00

VR Adviser Adds Over 1 Million Savara Shares

The Motley Fool • STOCK • 15/03/2026, 11:39:05

Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update

Business Wire • STOCK • 13/03/2026, 09:05:00

Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Business Wire • STOCK • 06/03/2026, 17:05:00

SAVARA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Savara, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

GlobeNewsWire • STOCK • 24/01/2026, 12:38:00